Deutsche Bank Ag\ Sigilon Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.74 - $1.64 $12,814 - $28,399	-17,317 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.24 - $3.03 $10,017 - $24,479	8,079 Added 87.45%	17,317 $25,000
Q4 2021 Feb 11, 2022	SELL	$2.58 - $6.13 $25,206 - $59,890	-9,770 Reduced 51.4%	9,238 $25,000
Q3 2021 Nov 04, 2021	BUY	$4.42 - $10.61 $63,192 - $151,691	14,297 Added 303.48%	19,008 $107,000
Q2 2021 Aug 11, 2021	SELL	$9.15 - $20.17 $101,107 - $222,878	-11,050 Reduced 70.11%	4,711 $51,000
Q1 2021 May 13, 2021	BUY	$18.76 - $40.91 $295,676 - $644,782	15,761 New	15,761 $352,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.